Literature DB >> 20022965

Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells.

Jane L Armstrong1, Ross Flockhart, Gareth J Veal, Penny E Lovat, Christopher P F Redfern.   

Abstract

The neuroectodermal tumors neuroblastoma and melanoma represent biologically aggressive and chemoresistant cancers. The chemotherapeutic agents fenretinide and bortezomib induce apoptosis through endoplasmic reticulum (ER) stress in these tumor types. The aim of this study was to test the hypothesis that the early events of ER stress signaling and response pathways induced by fenretinide and bortezomib are mediated by the eukaryotic initiation factor 2alpha (eIF2alpha)-ATF4 signaling pathway. Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34. These events correlated with induction of the pro-apoptotic protein Noxa. The cytotoxic response, characterized by up-regulation of Noxa and cell death, was dependent on ATF4, but not the ER-related pro-death signaling pathways involving GADD153 or IRE1. Although PERK-dependent phosphorylation of eIF2alpha enhanced ATF4 protein levels during ER stress, cell death in response to fenretinide, bortezomib, or thapsigargin was not abrogated by inhibition of eIF2alpha phosphorylation through PERK knockdown or overexpression of wild-type eIF2alpha. Furthermore, ATF4 induction in response to ER stress was dependent primarily on transcriptional activation, which occurred in a PERK- and phosphorylated eIF2alpha-independent manner. These results demonstrate that ATF4 mediates ER stress-induced cell death of neuroectodermal tumor cells in response to fenretinide or bortezomib. Understanding the complex regulation of cell death pathways in response to ER stress-inducing drugs has the potential to reveal novel therapeutic targets, thus allowing the development of improved treatment strategies to overcome chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022965      PMCID: PMC2825403          DOI: 10.1074/jbc.M109.014092

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Expression of the stress-associated protein p8 is a requisite for tumor development.

Authors:  Juan L Iovanna
Journal:  Int J Gastrointest Cancer       Date:  2002

2.  Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Authors:  J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

3.  Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma.

Authors:  P E Lovat; M Ranalli; M Annichiarrico-Petruzzelli; F Bernassola; M Piacentini; A J Malcolm; A D Pearson; G Melino; C P Redfern
Journal:  Exp Cell Res       Date:  2000-10-10       Impact factor: 3.905

4.  In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.

Authors:  Lizzia Raffaghello; Gabriella Pagnan; Fabio Pastorino; Emilio Cosimo; Chiara Brignole; Danilo Marimpietri; Paolo G Montaldo; Claudia Gambini; Theresa M Allen; Emil Bogenmann; Mirco Ponzoni
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

5.  Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress.

Authors:  Yanjun Ma; Linda M Hendershot
Journal:  J Biol Chem       Date:  2003-07-01       Impact factor: 5.157

6.  Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells.

Authors:  Krishna M Vattem; Ronald C Wek
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

7.  Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response.

Authors:  Hao-Yuan Jiang; Sheree A Wek; Barbara C McGrath; Dan Lu; Tsonwin Hai; Heather P Harding; Xiaozhong Wang; David Ron; Douglas R Cavener; Ronald C Wek
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

8.  Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2.

Authors:  Matthew H Brush; Douglas C Weiser; Shirish Shenolikar
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

9.  Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.

Authors:  David S Hill; Shaun Martin; Jane L Armstrong; Ross Flockhart; Joge J Tonison; Dominic G Simpson; Mark A Birch-Machin; Christopher P F Redfern; Penny E Lovat
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response.

Authors:  Phoebe D Lu; Heather P Harding; David Ron
Journal:  J Cell Biol       Date:  2004-10-11       Impact factor: 10.539

View more
  77 in total

1.  KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Authors:  Sudha Mannava; DaZhong Zhuang; Jayakumar R Nair; Rajat Bansal; Joseph A Wawrzyniak; Shoshanna N Zucker; Emily E Fink; Kalyana C Moparthy; Qiang Hu; Song Liu; Lawrence H Boise; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Β-adrenergic receptor stimulation induces endoplasmic reticulum stress in adult cardiac myocytes: role in apoptosis.

Authors:  Suman Dalal; Cerrone R Foster; Bhudev C Das; Mahipal Singh; Krishna Singh
Journal:  Mol Cell Biochem       Date:  2012-01-21       Impact factor: 3.396

3.  Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.

Authors:  Mohammad A Shahshahan; Maureen N Beckley; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2011-08-23       Impact factor: 6.166

Review 4.  Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy.

Authors:  Yanfen Liu; Yihong Ye
Journal:  Cell Res       Date:  2011-05-03       Impact factor: 25.617

Review 5.  The P5 disulfide switch: taming the aging unfolded protein response.

Authors:  Akash Mathew
Journal:  Cell Stress Chaperones       Date:  2015-06-05       Impact factor: 3.667

6.  A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.

Authors:  Rozita Bagheri-Yarmand; Krishna M Sinha; Anupama E Gururaj; Zamal Ahmed; Yasmeen Q Rizvi; Su-Chen Huang; John E Ladbury; Oliver Bogler; Michelle D Williams; Gilbert J Cote; Robert F Gagel
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

7.  Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Krishna M Sinha; Ling Li; Yue Lu; Gilbert J Cote; Steven I Sherman; Robert F Gagel
Journal:  Mol Cancer Res       Date:  2018-12-14       Impact factor: 5.852

8.  Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms.

Authors:  Ivana Pilchova; Katarina Klacanova; Katarina Dibdiakova; Simona Saksonova; Andrea Stefanikova; Eva Vidomanova; Lucia Lichardusova; Jozef Hatok; Peter Racay
Journal:  Neurochem Res       Date:  2017-07-19       Impact factor: 3.996

9.  Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.

Authors:  Justin T Babcock; Hoa B Nguyen; Yujun He; Jeremiah W Hendricks; Ronald C Wek; Lawrence A Quilliam
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

10.  The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.

Authors:  Qiuyan Wang; Bidhan A Shinkre; Jin-gu Lee; Marc A Weniger; Yanfen Liu; Weiping Chen; Adrian Wiestner; William C Trenkle; Yihong Ye
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.